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Purpose: Crushed tablet and solution formulations
of apixaban administered orally or via a nasogastric
tube (NGT) may be useful in patients unable to
swallow solid dose formulations. It is important to
understand whether new formulations and/or meth-
ods of administration impact apixaban bioavailability
and pharmacokinetic properties. These studies eval-
uated the relative bioavailability (Frel) of apixaban
solution administered orally; oral solution adminis-
tered via NGT ﬂushed with either 5% dextrose in
water (D5W) or with infant formula; oral solution via
NGT with a nutritional supplement; and crushed
tablet suspended in D5W and administered via NGT.
Methods: Three open-label, randomized, crossover
studies were conducted in healthy adults (study 1:
apixaban 10-mg tablet [reference] versus oral solu-
tion, both administered PO; study 2: apixaban 5-mg
oral solution PO [reference] versus oral solution via
NGT ﬂushed with either D5W or infant formula;
study 3: apixaban 5-mg oral solution PO [reference]
versus apixaban 5-mg oral solution via NGT with a
nutritional supplement and versus crushed tablet
suspended in D5W and administered via NGT). Point
estimates and 90% CIs of the geometric mean ratios
(GMRs; test/reference) were generated for Cmax and
AUC. Adverse events were recorded throughout
each study.
Findings: Frel of the oral solution was 105% versus
tablet, and Frel for oral solution via NGT with D5W
ﬂush, infant formula ﬂush, nutritional supplement,
and crushed tablet via NGT versus oral solution
administration were 96.7%, 92.2%, 81.3%, and
95.1%, respectively. The 90% CIs of the GMRs of
all AUCs met the bioequivalence criterion except that
of the nutritional supplement (0.766–0.863). The
corresponding GMRs for Cmax were 0.977, 0.953,
0.805, 0.682, and 0.884. For the solution via NGTAugust 2015ﬂushed with D5W and for the crushed tablet, the 90%
CIs of the Cmax GMRs met the bioequivalence
criterion. Apixaban was well tolerated in all 3 studies;
most adverse events were mild.
Implications: Comparable Frel was observed for oral
apixaban solution, tablet, NGT administration of solu-
tion ﬂushed with D5W and infant formula, and NGT
administration of crushed tablet suspension. Exposure
was less when oral solution was administered via NGT
with nutritional supplement. These results support sev-
eral alternative methods of administering apixaban that
may be useful in certain clinical situations. ClinicalTrials.
gov identiﬁers: NCT02034565, NCT02034578, and NC
T02034591. (Clin Ther. 2015;37:1703–1712) & 2015
The Authors. Published by Elsevier HS Journals, Inc.
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Apixaban is an oral, selective, direct reversible factor
Xa inhibitor recently approved for use in the Euro-
pean Union, the United States, and other countries for
stroke prevention in patients with atrial ﬁbrillation,1,2
for thromboprophylaxis after elective hip- or knee-
replacement surgery,3,4 and for the treatment of
venous thromboembolism.5,6 Apixaban is available
as ﬁlm-coated immediate-release 2.5- and 5-mg
tablets.7
Apixaban is a Biopharmaceutics Classiﬁcation
System Class III compound (high solubility/low1703
Clinical Therapeuticspermeability),8 and is non-ionizable; thus, changes in
pH do not affect the aqueous solubility of apixaban.
Given orally, the bioavailability of apixaban tablets is
50%,7 and apixaban is absorbed primarily in the
upper gastrointestinal (GI) tract, proximal to the
colon.9 The Tmax of the apixaban tablet formulation
is 3 hours after oral administration in healthy
subjects, and the t1/2 is 12 hours (range, 8–15
hours).10 Elimination occurs through multiple
pathways (including renal elimination, metabolism,
and biliary and intestinal excretion), with renal
clearance accounting for 27% of total clearance.11,12
Dysphagia, or difﬁculty swallowing, occurs in
6% to 27% of the elderly population, and pediatric
patientsr5 years of age are often not able to swallow
the oral dose formulations.13–18 Patients with dyspha-
gia may delay taking medication or skip the medi-
cation entirely,19 and clinicians will often seek
alternate methods of administration. Under these
circumstances, and if a liquid formulation is not
readily available, solid oral formulations are often
crushed and mixed with liquids or semisolid foods.20
These extemporaneous manipulations of solid oral
dose formulations can signiﬁcantly impact the
pharmacokinetic properties of a drug.
In addition, crushed tablet preparations, as well as
liquid formulations, are often administered through a
nasogastric tube (NGT), and clinical practices can vary
signiﬁcantly. For example, the administration of a
medication via NGT using a ﬂush of 5% dextrose in
water (D5W) may be preferred in infants who have no
ﬂuid restrictions, whereas the administration of a
medication during an enteral feeding may be preferred
in infants with ﬂuid restrictions.21 Likewise, medication
is sometimes administered via NGT in adults who have
difﬁculty swallowing and are receiving enteral
nutrition.22 Therefore, it is important to understand
whether the method of administration under these
conditions has an effect on the bioavailability and
pharmacokinetic properties of a treatment.
Crushed apixaban tablets or an apixaban solution
formulation could be useful for patients unable to
swallow solid tablets. In in vitro experiments, near-
complete apixaban recovery was achieved when apix-
aban solution was ﬂushed through an NGT (Kendall
Entriﬂex dual-port feeding tube [Covidien, Mansﬁeld,
Massachusetts] with a weighted ﬂow-through stylet
[10 Fr (diameter), 109 cm (length)]) by D5W, and
crushed tablets were stable in water and D5W for up1704to 4 hours (BMS, 2014). Therefore, 3 clinical studies
were conducted to assess the relative bioavailability
(Frel) of an apixaban oral solution administered orally
versus that of apixaban oral solution or crushed




This was an open-label, randomized, 2-way cross-
over study of single-dose apixaban administered in the
fasted state. The primary objective of this study was to
compared the Frel of apixaban oral solution with that
of a tablet formulation. It was conducted at MDS
Pharma Services (Neptune, New Jersey), and the
protocol was approved by MDS Pharma Services
IRB (Lincoln, Nebraska). Healthy subjects were ran-
domly assigned in a 1:1 ratio to receive a single oral
dose of apixaban 10 mg as either 2  5 mg tablets or
25 mL  0.4 mg/mL solution.
Study 2 (NCT02034578)
This was an open-label, 3-treatment, 3-period,
randomized, crossover study of single-dose apixaban.
The primary objectives of this study were to compare
the Frel of apixaban oral solution administered via an
NGT ﬂushed with either D5W or infant formula with
that of the oral solution formulation administered by
mouth. It was conducted at Parexel Baltimore Early
Phase Clinical Unit (Baltimore, Maryland), and the
protocol was approved by ASPIRE IRB (La Mesa,
California). Healthy subjects received apixaban 5 mg
(12.5 mL  0.4 mg/mL oral solution) administered via
oral syringe with 240 mL of water; via an NGT
ﬂushed with 60 mL of D5W, then with 180 mL of
water administered orally; and via an NGT immedi-
ately followed by 60 mL of infant formula (Similacs
Advances Ready-to-Feed Infant Formula with Iron;
Abbott Nutrition, Columbus, Ohio), then with 180
mL of water administered orally.
A 10-Fr, 109-cm Kendall Entriﬂex dual-port feed-
ing tube (Covidien) with a weighted ﬂow-through
stylet was used in this study. The tip of the NGT
was placed in the stomach, as conﬁrmed by
radiography.
Study 3 (NCT02034591)
This was an open-label, 3-treatment, 3-period,
randomized, crossover study of a single dose ofVolume 37 Number 8
Y. Song et al.apixaban. The primary objectives of this study were to
compare the Frel of an apixaban oral solution admin-
istered via an NGT ﬂushed with a nutritional supple-
ment or of a crushed tablet suspended in D5W
administered via an NGT with that of the oral
solution formulation administered by mouth. The
study was conducted at Healthcare Discoveries, LLC
(San Antonio, Texas) and the protocol was approved
by the IntegReview Ethical Review Board (Austin,
Texas). Healthy subjects received apixaban 5 mg as a
solution via an oral syringe; as a solution via an NGT
administered with a 240-mL nutritional supplement*
and as a crushed tablet suspended in 60 mL of D5W
via an NGT.
The apixaban solution was administered via NGT
immediately after 180 mL of the nutritional supple-
ment, with an additional 60 mL of the nutritional
supplement administered via the NGT after the apix-
aban dose. For the crushed tablet administration, a
single 5-mg apixaban tablet was crushed into a ﬁne
powder using a mortar and pestle and suspended in
60 mL D5W. This suspension was administered
through an NGT. The mortar and pestle were rinsed
3 times with approximately 60 mL of water each time,
and the rinsing solution was administered via the NGT.
A 10-Fr (diameter), 114-cm (length) enteral feeding
tube (Abbott), preassembled with stylet, and tungsten-
weighted bolus, with water-activated lubricant was
used in this study. The tip of the NGT was placed in
the stomach, as conﬁrmed by radiography.
All studies complied with all local regulations, the
Declaration of Helsinki, and the International Conference
on Harmonisation Guidelines on Good Clinical Practice.Study Population and Timetable
Study participants were healthy subjects, deﬁned as
having no clinically signiﬁcant deviation from normal
values on medical history, physical examination,
ECG, and clinical laboratory determinations. Subjects
were eligible if they were aged 18 to 45 years, with a
body mass index of 18 to 30 kg/m2. Women of
childbearing potential had to have a negative serum
pregnancy test within 24 hours before starting admin-
istration of the investigational product. All subjects
were required to provide written informed consent
before participation. Exclusion criteria included any*(Boost Pluss nutritional drink; Nestlé HealthCare Nutrition,
Fremont, Michigan)
August 2015history or evidence of abnormal bleeding or coagu-
lation disorders; history of any GI surgery or other
conditions or treatment with concurrent medications
that could affect the absorption of the study drug; and
current or recent (within 3 months) GI disease
including, but not limited to, dyspepsia, GI ulcers,
esophageal or gastric varices, and hemorrhoids.
For all 3 studies, subjects were admitted to the
clinical facility on day 1 and remained at the clinical
facility for the duration of the study. Randomization
to treatment sequence was carried out according to a
computer-generated randomization scheme supplied
by the sponsor. Apixaban was dosed immediately
after a 10-hour overnight fast in each treatment
period. All studies included a minimum 4-day wash-
out period between treatments.Pharmacokinetic Assessments
Blood samples were collected by venipuncture or
indwelling catheter predose and at 0.25, 0.5, 1, 2, 3, 4,
5, 6, 9, 12, 24, 36, 48, 60, and 72 hours postdose in all 3
studies for the determination of apixaban plasma con-
centration. Apixaban in human plasma was assayed
using a validated liquid chromatography atmospheric
pressure ionization tandem-mass spectrometry method
with a lower limit of quantiﬁcation of 1 ng/mL during the
period of known analyte stability.23 The pharmacokinetic
parameters of apixaban were derived from plasma
concentration–time proﬁles using noncompartmental
methods from the individual plasma concentration–time
data using Kinetica version 5.0 (InnaPhase Corporation,
Philadelphia, Pennsylvania) within eToolbox (EP version
2.7; Thermo Electron Corporation, Philadelphia, Penn-
sylvania). The parameters included Cmax, AUC0–1,
AUC0–t, Tmax, and t½. Point estimates and 90% CIs of
the geometric mean ratios (GMRs; test/reference) were
generated for the comparison of Cmax, AUC0–1, and
AUC0–t between treatments. Frel was deﬁned as the ratio
of test AUC0–1/reference AUC0–1, expressed as a
percentage. All analyses were performed using SAS
version 9.2 (SAS Institute, Cary, North Carolina).Tolerability Assessments
Tolerability assessments were based on adverse-
events reports and the results of physical examinations
including vital sign measurements, 12-lead ECG, and
clinical laboratory tests performed at baseline and
selected times throughout the study.1705
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In study 1, although the sample size was not based
on statistical power considerations, it was calculated
that 12 subjects would provide 90% conﬁdence that
the estimates of the GMRs (solution/tablet) for Cmax
and AUC were within 14% and 13% of the true
values, respectively. To allow for dropouts, 14 sub-
jects were dosed. In studies 2 and 3, it was calculated
that 18 subjects would provide 85% power to con-
clude similar bioavailability with respect to Cmax and
91% power with respect to AUC. Similar bioavail-
ability would be concluded if the 90% CIs of the
population GMRs of apixaban as an oral solution
compared with other methods of administration were
wholly contained within the prespeciﬁed bioequiva-
lence range of 0.80 to 1.25. The calculation assumed
that Cmax and AUC were log-normally distributed,
with intrasubject SDs of 0.20 for log(Cmax) and 0.19
for log(AUC0–1).
24 Studies 2 and 3 included 21
subjects each to allow for dropouts.RESULTS
Demographic Characteristics and Subject
Disposition
A summary of the baseline demographic and clinical
characteristics of all subjects randomized to treatmentTable I. Baseline demographic and clinical characteristics
apixaban oral solution or crushed tablets admin
Characteristic Study 1 (n ¼ 14)
Age, y






Black/African American 8 (57)
White 6 (43)
Body mass index, kg/m2
Mean (SD) 25.5 (3.5)
Range 19.3–29.6
Weight, kg
Mean (SD) 78.0 (13.0)
Range 54.8–101.7
1706in the 3 studies is shown in Table I. With the exception
of 1 subject (7%) in study 1 who discontinued because
of an adverse event and 1 subject in study 3 who
withdrew consent on day 4 of the ﬁrst treatment
period, all subjects completed the studies.Pharmacokinetic Properties
The pharmacokinetic properties of apixaban are
summarized in Table II and in the Figure. Mean Cmax,
AUC0–1, and AUC0–t were similar between the tablet
and oral solution formulations. The Frel of apixaban
solution versus tablet was 105.0% (90% CI, 93.8–
117.6), and the GMR for Cmax was 0.977 (90% CI,
0.756–1.261).
The Frel values of apixaban solution administered
via an NGT and ﬂushed with 60 mL of D5W and with
60 mL of infant formula were 96.7% and 92.2%,
respectively, relative to orally administered apixaban
solution. The GMRs of the Cmax values of apixaban
solution administered via an NGT and ﬂushed with
D5W and infant formula were 0.953 and 0.805,
respectively, relative to orally administered apixaban
solution. With the exception of Cmax after infant
formula ﬂush, the 90% CI for exposure parameter
GMRs fell entirely within the predeﬁned bioequiva-
lence criterion (0.80–1.25).of the subjects in this study of the bioavailability of
istered by mouth or nasogastric tube.
Study 2 (n ¼ 21) Study 3 (n ¼ 21)
33 (6.7) 36.7 (6.9)
21–45 22–45
13 (62) 13 (62)
8 (38) 8 (38)
18 (86) 6 (29)
3 (14) 15 (71)
25.4 (2.2) 26.1 (2.4)
21.4–28.5 21.3–29.3
75.6 (9.3) 75.2 (12.4)
56.7–93.4 56.5–98.4
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Table II. Pharmacokinetic (PK) properties of apixaban: statistical analysis.
PK Parameter
Apixaban 10 mg (Study 1; n ¼ 14)






(ref)Oral Solution PO* Tablet PO† (ref) D5W Flush
‡ Infant Formula Flush§
Oral Solution With
Nutritional Supplement¶




287 (30) 294 (37) 180 (22) 153 (20) 189 (23) 121 (21) 158 (22) 177 (19)




2855 (21) 2707 (21) 1239 (25) 1181 (26) 1280 (21) 1122 (18) 1321 (18) 1380 (15)
GMR (90% CI) – 1.050 (0.938–1.176) 0.968 (0.926–1.011) 0.922 (0.899–0.947) – 0.813 (0.766–0.863) 0.950 (0.905–0.997) –
AUC0–t, ng  h/
mL, GM (%
CV)
2790 (21) 2663 (22) 1214 (26) 1154 (26) 1257 (21) 1098 (18) 1295 (18) 1354 (15)
GMR (90% CI) – 1.043 (0.933–1.167) 0.966 (0.924–1.010) 0.919 (0.896–0.942) – 0.810 (0.764–0.860) 0.947 (0.903–0.994) –
Tmax, h, median
(range)
2.00 (1.00–4.00) 2.00 (0.50–4.05) 1.00 (0.30–2.00) 1.00 (0.48–2.00) 0.52 (0.48–2.00) 3.00 (1.00–4.20) 1.00 (0.50–3.00) 1.00 (0.50–2.00)
t½, h, mean
(SD)
13.8 (6.1) 12.3 (4.5) 10.4 (4.5) 10.6 (3.8) 10.5 (4.2) 9.6 (2.4) 10.4 (7.8) 11.2 (6.9)
Frel, %, GM (%
CV)
105# NA 96.7 (11) 92.2 (7) NA 81.3 (16) 95.1 (13) NA
CI = conﬁdence interval; D5W ¼ 5% dextrose in water; Frel ¼ relative bioavailability; GM ¼ geometric mean; GMR ¼ geometric mean ratio versus reference (ref),
estimated from general linear mixed-effects models; NGT ¼ nasogastric tube.
*25 mL  0.4 mL, administered via oral syringe.
**One 5-mg crushed tablet, suspended in 60 mL D5W.
†Two 5-mg tablets administered orally.
‡12.5 mL  0.4 mg/mL, immediately followed by 60 mL D5W.
§12.5 mL  0.4 mg/mL, immediately followed by 60 mL of infant formula.
‖12.5 mL  0.4 mg/mL, administered via oral syringe.
¶12.5 mL  0.4 mg/mL, with nutritional supplement; 1 subject discontinued treatment in the ﬁrst treatment period.
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Apixaban tablets 2 x 5 mg  administered orally (n=13*)
Apixaban solution 10 mg (25 mL x 0.4 mg/mL) 
administered via oral syringe (n=13)
Apixaban solution 5 mg (12.5 mL x 0.4 mg/mL) administered via oral syringe (n=20)
Apixaban solution 5 mg (12.5 mL x 0.4 mg/mL) after Boost Plus® via NGT (n=20)
Apixaban 5 mg crushed tablet suspended in 60 mL D5W administered via NGT (n=21)
Treatments
Apixaban solution 5 mg (12.5 mL x 0.4 mg/mL) 
administered via oral syringe (n=21)
Apixaban solution 5 mg (12.5 mL x 0.4 mg/mL) 
administered via NGT immediately followed
by 60 mL of D5W via NGT (n=21)
Apixaban solution 5 mg (12.5 mL x 0.4 mg/mL) 
administered via NGT immediately followed by 
















































Figure. Plasma concentration–time profiles of single-dose apixaban in studies 1 (A), 2 (B), and 3 (C). Inset
shows the first 24 hours after administration on a linear scale. Error bars show þ1 SD. *n ¼ 14 for 0–12
hours. D5W, 5% dextrose in water; NGT, nasogastric tube. Boost Plus is a trademark of Nestle´
HealthCare Nutrition, (Fremont, Michigan).
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tered through an NGT and apixaban solution adminis-
tered via an NGT in the presence of the nutritional
supplement were 95.1% and 81.3%, respectively, relative
to orally administered apixaban solution. When apixaban
crushed tablet suspended in D5W was administered via
an NGT, Cmax and AUC were similar, with the 90% CIs
of the estimated GMRs of Cmax, AUC0–1, and AUC0–t
falling entirely within the predeﬁned bioequivalence CI
(0.80–1.25). When apixaban solution was given via an
NGT in the presence of the nutritional supplement,
apixaban Cmax and AUC were 32% and 19% less,
respectively, than the corresponding values observed after
oral administration of the apixaban solution.
Regardless of formulation or route of administration,
the mean t½ of apixaban was similar, 12 hours (range,
9.6–13.8 hours in each of the 3 studies). Median Tmax
was 0.5 to 2 hours with the tablet and solution
administered orally, the solution administered through
an NGT, and the crushed tablet given via an NGT.
Median Tmax was 3 hours after administration of the
solution via an NGT in the presence of the nutritional
supplement.
Tolerability
Apixaban was well tolerated in all 3 studies, regard-
less of the route of administration. The majority of
adverse events were mild, and the most common adverse
event was headache, which occurred in 2 subjects in
studies 1 and 2, and in 3 subjects in study 3. No adverse
events rated as moderate or severe in intensity were
reported in Study 1, one moderate adverse event (head-
ache, considered not related to study drug) was reported
in Study 2, and two moderate adverse events (headache,
considered related to study drug; paronychia, considered
not related to study drug) were reported in Study 3. No
bleeding-related adverse events were reported in any of
the studies. One serious adverse event, gastric carci-
noma, was reported in study 3; however, it was
determined that this condition was present before the
start of the study. One subject withdrew from study 1
because of a toothache that was not considered related
to study drug. None of the physical examination or
ECG ﬁndings were considered to be of clinical impor-
tance by the investigators in the respective studies.
DISCUSSION
Apixaban is an immediate-release tablet formulation with
rapid dissolution, pH-independent aqueous solubility,August 2015and no clinically relevant food effect.25 Therefore, it is
not surprising that ﬁndings from these studies showed
that the pharmacokinetic properties of apixaban were
comparable after oral administration of the tablet and
solution formulations, and between methods of
administration. Oral administration of apixaban
solution was associated with AUCs similar to those
obtained after the administration of apixaban tablets,
indicating that dissolution of the tablet does not affect the
extent of apixaban absorption. Although no-effect criteria
were not predeﬁned for this study, the 90% CI of the
GMR of AUC0–1 was within the widely accepted
bioequivalence boundaries (ie, 0.80–1.25). The GMR of
Cmax was also close to unity (0.98), and although the
90% CI (0.756–1.26) extended beyond the bioequiva-
lence interval, this was likely a reﬂection of the study’s
relatively small sample size. This result suggests that the
rate of apixaban absorption of the solution formulation is
similar to that of the tablet formulation. It is likely that
the CIs for Cmax would have met the typical bioequiva-
lence criteria if the study sample size had been larger
(18 subjects based on the observed variability). Because
the solution and tablet formulations were essentially
bioequivalent, the solution formulation was considered
to be a reasonable reference treatment for the 2 sub-
sequent studies evaluating administration via NGT.
A variety of NGTs of different lengths, sizes (outer
diameter), and materials are used in clinical practice.
When a drug is administered via an NGT, there is
potential for the drug to adsorb onto the tubing,
leading to loss of the dose.26 In addition, different
volumes of ﬂushing media may be utilized after drug
administration via an NGT, and an insufﬁcient ﬂush
volume could also contribute to underdosing. Based
on data from in vitro experiments, ﬂushing the
apixaban solution through an NGT (the same as the
one used in study 2) with 25 mL of D5W was
associated with near-complete (495%) apixaban
recovery at the 1-mL apixaban solution dose (BMS,
2010 and 2011). This ﬁnding suggests that apixaban
does not adhere to the NGT and that administration
through an NGT results in complete dose delivery.
The feeding tubes used in these studies were 10 Fr,
110 cm (length), and made with polyurethane,
similar to those commonly used in both adult and
pediatric patients. Taking these in vitro data, as well
as the differences in NGT length and diameter, into
consideration, 60 mL of D5W or infant formula was
selected to be administered after apixaban solution1709
Clinical Therapeuticsthrough an NGT. Indeed, the bioavailability of apix-
aban solution administered via an NGT and ﬂushed
with D5W or infant formula was found to be generally
comparable with that of apixaban solution adminis-
tered orally (97% and 92%, respectively), suggesting
that both D5W and infant formula can be used for
ﬂushing the apixaban solution through an NGT.
These results further demonstrate that apixaban does
not adsorb into the NGT.
NGT placement is another important consideration
when administering medication by this route. Depend-
ing on the characteristics of the drug, i.e. the absorp-
tion site and the physical–chemical properties of the
drug, the location of the feeding tube may affect the
extent of drug absorption. For example, the Frel of
ketoconazole is less when ketoconazole is adminis-
tered through a jejunostomy tube versus that expected
with oral administration.27 When apixaban is
delivered directly to the distal small bowel and the
ascending colon, apixaban exposure is 40% and 10%
of that achieved after oral administration, indicating
the upper GI tract (duodenum, jejunum, and ileum) as
the primary absorption region.9 NGT placement in
the stomach was conﬁrmed by radiography in these
studies, and although apixaban is readily absorbed
from the upper GI tract, it is not known whether
similar results would have been obtained if the NGT
were placed in the small intestine.
Apixaban absorption appeared to have occurred
more slowly after administration of the solution via an
NGT in the presence of a nutritional supplement
compared with administration via an oral syringe,
with Tmax at 3 hours postdose, a delay of 2 hours
relative to fasted administration via an oral syringe.
This delay in the Tmax is a common observation for
orally administered medicines given with a meal and
probably reﬂects prolonged emptying of the stomach
in the presence of food.28 In a dedicated food-effect
study in which apixaban tablets were administered
orally, there was no clinically signiﬁcant effect of food
on apixaban exposure, but a delay in Tmax was
reported.25 As food intake and administration
through an NGT do not individually affect apixaban
pharmacokinetic properties, the observed effects of
the nutritional supplement combined with NGT
administration on the pharmacokinetic properties of
apixaban solution formulation remain to be
elucidated and may be inﬂuenced by a combination
of factors in situ. Although stability in the nutritional1710supplement has not been evaluated, based on existing
stability data demonstrating that crushed apixaban
tablets are stable in water, D5W, apple juice, and
applesauce for up to 4 hours (BMS, 2014), it is not
expected that apixaban stability in the nutritional
supplement is a confounding factor, especially given
that the supplement and apixaban were administered
sequentially.
Mixing capsule contents or crushed tablets with
semisolid foods or liquids is a common approach to
administering medications in patients who have difﬁ-
culty swallowing solid dose formulations; often this is
done without determining whether these extempora-
neous procedures impact drug stability or bioavail-
ability. When studied, the Frel may be found to be
greatly impacted. For example, when clopidogrel was
crushed and administered via an NGT compared with
a whole tablet administered orally, the Tmax was less
(44 vs 70 minutes) and Cmax was 80% greater.
29 In
another example, the oral bioavailability of dabigatran
etexilate increased by 75% when the pellets were taken
without the capsule shell compared with that of the
intact capsule formulation.30 Two case studies have
reported that when warfarin was administered with a
nutritional supplement via NGT, persistent
subtherapeutic prothrombin times were observed.31
In vitro results from the same publication suggested
that warfarin is bound to certain components within
the nutritional supplement. Results from the present
studies suggest that apixaban tablets can be crushed
and administered through an NGT without an effect
on Frel. Because apixaban bioavailability was not
affected by administration via NGT and there was
comparable bioavailability between the intact tablet
and the solution, it is expected that the administration
of the crushed tablet and intact tablet would result in
comparable exposure.CONCLUSIONS
Overall, these results support several alternative meth-
ods of apixaban administration in patients who are
unable to swallow solid oral dose formulations.
Although the administration of apixaban with a
nutritional supplement was associated with a lesser
apixaban exposure, the impact on apixaban AUC was
limited. The data on apixaban Frel support the
administration of the solution via an NGT using
D5W or infant formula as a ﬂush medium, as wellVolume 37 Number 8
Y. Song et al.as the administration of crushed apixaban tablets
suspended in D5W via an NGT.ACKNOWLEDGMENTS
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